VZV IgM ELISA

The Calbiotech VZV IgM ELISA Kit is intended for the detection of IgM antibody to VZV in human serum or plasma.


Catalog No Size
Product Catalog No: VZ082M Pack Size: 96 Tests

Pack Size:
Pack Size:
Pack Size:
Pack Size:

Category:
Summary

Varicella zoster virus causes chickenpox a highly contagious disease acquired by touching the blisters or respiratory secretions, or through the air. A person is usually infectious 1-2 days before the rash to 4-5 days after the start of the rash, or until the blisters have formed crusts. Symptoms start about 2-3 weeks after exposure and include fever, tiredness, and an itchy rash with small blisters that dry up and form scabs in 2-4 days. More severe but rare problems or complications that could occur are pneumonia (especially in adults), skin infection, blood infection and encephalitis. Approximately 90% of chickenpox cases are in children 1-14 years of age, and 90% of people have had chickenpox by their early 20’s. The reactivated form (herpes zoster: shingles) of VZV infection generally occurs in older adults whose immunity has waned, in infants or children exposed to VZV in the perinatal period or in the immunocompromised. VZV infection during pregnancy infrequently leads to maternal pneumonia. Chickenpox can occur during pregnancy in women seropositive for VZV, especially when seropositive at low titer, with low-avidity, largely IgG3 antibodies. Maternal VZV infection during pregnancy (especially between 13-20 weeks gestation) can be associated with outcomes ranging from skin scarring or limb hypoplasia to multi system involvement and death. Because VZV and herpes simplex virus (HSV) can cross-react, viral culture can be used to detect and differentiate HSV from VZV, but PCR testing may prove the most valuable for diagnosing and differentiating active infection. IgG antibodies can be detected 9 days after the onset of rash in varicella, 10 days in zoster; immunoreactivity peaks at an average 66 and 27 days, respectively. The IgM response to varicella is detected at 6-7 days post-onset and peaks at an average 14 days; IgM response to zoster is detectable at 8-10 days and peaks at 18-19 days.

Test Principle

Diluted patient serum (serum diluent contains sorbent to remove Rheumatoid Factor and human IgG interference) is added to wells coated with purified antigen. IgM specific antibody, if present, binds to the antigen. All unbound materials are washed away and the enzyme conjugate is added to bind to the antibody-antigen complex, if present. Excess enzyme conjugate is washed off and substrate is added. The plate is incubated to allow the hydrolysis of the substrate by the enzyme. The intensity of the color generated is proportional to the amount of IgM specific antibody in the sample.

Order Enquiry

Order Enquiry Form

References
  1. Weinberg A, Hayward AR, Masters HB, Obu IA, Levin MJ. Comparison of two methods for detecting varicella-zoster virus antibody with varicella-zoster cell-mediated immunity. J Clin Microbiol 1996;34:445-6.
  2. Unadkat P, Newman B, Tedder RS. The detection of varicella zoster antibodies by simultaneous competitive EIA and its comparison with radioimmunoassay, latex agglutination and antiglobulin type EIA. J Virol Methods 1995;51:145-52.
  3. Junker AK, Tilley P. Varicella-zoster virus antibody avidity and IgG-subclass patterns in children with recurrent chickenpox. J Med Virol 1994;43:119-24.
  4. Balfour HH Jr, Edelman CK, Dirksen CL, et al. Laboratory studies of acute varicella and varicella immune status. Diagn Microbiol Infect Dis 1988;10:149-58.
  5. Cohen PR. Tests for detecting herpes simplex virus and varicella-zoster virus infections. Dermatol Clin 1994;12:51-68.
  6. Ghodratnama F; Wray D; Bagg J Detection of serum antibodies against cytomegalovirus, varicella zoster virus and human herpesvirus 6 in patients with recurrent aphthous stomatitis. J Oral Pathol Med 1999; 28(1): 12-5.
  7. Gil A; Gonz´alez A; Dal-R´e R; Ortega P; Dominguez V. Prevalence of antibodies against varicella zoster, herpes simplex (types 1 and 2), hepatitis B and hepatitis A viruses among Spanish adolescents. J Infect 1988; 36(1):53-6.
Enquiry